Pulse Biosciences shares surpass 200 DMA, rising 4.9% on Thursday.

Pulse Biosciences Inc (PLSE) shares crossed above their 200-day moving average of $17.34, reaching $17.88 per share. The stock is currently trading up 4.9% on the day. The 52-week range for PLSE is between $13.76 and $25, with a last trade of $17.31.

Pulse Biosciences Inc (PLSE) shares crossed above their 200-day moving average of $17.34, reaching $17.88 per share. The stock is currently trading up 4.9% on the day. The 52-week range for PLSE is between $13.76 and $25, with a last trade of $17.31.

The move comes amidst a period of regulatory momentum and clinical progress for the company. In its Q2 2025 earnings call, Pulse Biosciences reported a quarterly adjusted loss of 20 cents per share, missing analyst expectations of a loss of 26 cents per share [1]. Despite the loss, the company highlighted significant advancements in its nsPFA technology, particularly in thyroid and cardiac ablation markets.

The stock's recent surge can be attributed to several key factors. First, the company's CEO, Paul Le Violette, unveiled breakthrough progress in the nsPFA IDE submission and highlighted $106.3M in cash reserves at Canaccord [2]. Second, clinical data from thyroid and cardiac ablation trials have driven optimism, despite rising operational costs.

Technically, the stock's 200-day moving average at $17.34 has acted as a critical psychological barrier. The RSI remains neutral, while the MACD histogram's positive divergence hints at potential short-term strength [2]. Aggressive bulls may consider options like PLSE20251017C20, which offers 21.38% leverage with a delta of 0.307, for directional exposure and volatility [2].

However, investors should remain cautious. The company's widening GAAP net loss and rising cash burn are critical risks. The stock's 52-week range and recent price action suggest a volatile environment. Investors should monitor the $17.10 resistance level and $14.71 support zone for further price direction [2].

In conclusion, Pulse Biosciences Inc shares have crossed above their 200-day moving average, reaching $17.88 per share. The move is driven by regulatory momentum and clinical progress, but investors should remain vigilant regarding financial risks.

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U424L:0-pulse-biosciences-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[2] https://www.ainvest.com/news/pulse-biosciences-soars-10-33-regulatory-momentum-clinical-catalysts-fueling-surge-2508/